Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Symadex (C-1311) in metastatic breast cancer after anthracycline and taxane failure
2005-004257-96Phase 2Completed
- Sponsor
- Xanthus Pharmaceuticals, Inc.
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of C-1311 in breast cancer, sponsored by Xanthus Pharmaceuticals, Inc. Primary endpoint: Overall response rate. Started Nov 2005; status: completed.
02
Drugs
C-1311
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-004257-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004257-96.